P. Donahoe

发表

Detection of large-scale variation in the human genome

L. Feuk, Charles Lee, S. Scherer, 2004, Nature Genetics.

A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes

Francisco S. Roque, Z. Szallasi, S. Brunak, 2008, Proceedings of the National Academy of Sciences.

Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12.

P. Donahoe, T. Wang, A. Zervos, 1994, Science.

Dissecting spatio-temporal protein networks driving human heart development and related disorders

Francisco S. Roque, S. Brunak, J. Seidman, 2010, Molecular systems biology.

Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development

Ayellet V. Segrè, M. Daly, J. Rosenfeld, 2012, Proceedings of the National Academy of Sciences.

Ambiguous genitalia--etiology, diagnosis, and therapy.

P. Donahoe, D. Federman, 1995, Advances in endocrinology and metabolism.

Patents And literature

D. A. Small, A. Atkinson, P. Donahoe, 1985 .

Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Yan Zhou, Tim N Beck, Erica A Golemis, 2016, Cell reports.

Müllerian inhibiting substance: gene structure and mechanism of action of a fetal regressor.

P. Donahoe, E. G. Ninfa, M. Takahashi, 1987, Recent progress in hormone research.

The epithelial-mesenchymal interface of the male rate Mullerian duct: loss of basement membrane integrity and ductal regression.

P. Donahoe, R. Trelstad, K. Hayashi, 1982, Developmental biology.

Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium.

P. Donahoe, E. Oliva, J. Teixeira, 2005, Developmental Biology.

Phosphorylation events during Müllerian duct regression.

P. Donahoe, J. Hutson, M. Fallat, 1984, Science.

Regulation of sexual dimorphism in mammals.

P. Donahoe, C. Haqq, Patricia K. Donahoe, 1998, Physiological reviews.

Effect of dry and humidified gases on the respiratory epithelium in rabbits.

P. Donahoe, S. Marfatia, W. Hendren, 1975, Journal of pediatric surgery.

Müllerian inhibiting substance production associated with loss of oocytes and testicular differentiation in the transplanted mouse XX gonadal primordium.

P. Donahoe, M. Takahashi, T. Taketo, 1993, Biology of reproduction.

Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content.

P. Donahoe, D. Seifer, H. Behrman, 1993, The Journal of clinical endocrinology and metabolism.

MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs.

P. Donahoe, D. E. Kling, T. B. Kinane, 2002, American journal of physiology. Lung cellular and molecular physiology.

Prenatal hormones alter antioxidant enzymes and lung histology in rats with congenital diaphragmatic hernia.

P. Donahoe, D. Tibboel, J. D. de Jongste, 1997, The American journal of physiology.

Prenatal glucocorticoids improve pulmonary morphometrics in fetal sheep with congenital diaphragmatic hernia.

P. Donahoe, P. Losty, J. Schnitzer, 1997, Journal of pediatric surgery.

Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome

P. Donahoe, C. Bormann, D. Pépin, 2018, The Journal of clinical endocrinology and metabolism.

De novo frameshift mutation in COUP‐TFII (NR2F2) in human congenital diaphragmatic hernia

C. Bult, P. Donahoe, Jay M. Wilson, 2016, American journal of medical genetics. Part A.

Müllerian Inhibiting Substance Inhibits Branching Morphogenesis and Induces Apoptosis in Fetal Rat Lung.

P. Donahoe, R. Ezzell, J. Teixeira, 1997, Endocrinology.

Developmental expression of a candidate müllerian inhibiting substance type II receptor.

P. Donahoe, J. Teixeira, E. Catlin, 1996, Endocrinology.

Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.

P. Donahoe, D. Maclaughlin, T. Manganaro, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Liver transplantation in children: the Boston Center experience in the first 30 months.

P. Donahoe, J. Vacanti, A. Cosimi, 1987, Transplantation proceedings.

Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation.

P. Donahoe, P. Sluss, J. Teixeira, 2002, Endocrinology.

Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.

P. Donahoe, J. Vacanti, A. Stephen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo

P. Donahoe, J. Vacanti, D. Segev, 2001, Proceedings of the National Academy of Sciences of the United States of America.

c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.

P. Donahoe, Lihua Zhang, J. Teixeira, 2008, Endocrinology.

Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor–Directed Transgenic Mouse Ovarian Cancers In vivo

P. Donahoe, E. Halpern, D. Connolly, 2006, Clinical Cancer Research.

The ontogeny of mullerian inhibiting substance in granulosa cells of the bovine ovarian follicle.

P. Donahoe, M. Takahashi, M. Hayashi, 1986, Biology of reproduction.

Uterine Leiomyomas Exhibit Fewer Stem/Progenitor Cell Characteristics When Compared With Corresponding Normal Myometrium

P. Donahoe, F. Preffer, D. Dombkowski, 2010, Reproductive Sciences.

Somatic stem cells of the ovary and their relationship to human ovarian cancers

P. Donahoe, D. Maclaughlin, Henry L. Chang, 2009 .

Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.

P. Donahoe, G. Budzik, A. Fuller, 1985, Gynecologic oncology.

Meiosis I Arrest Abnormalities Lead to Severe Oligozoospermia in Meiosis 1 Arresting Protein (M1ap)-Deficient Mice1

P. Donahoe, Naifang Lu, J. McCarrey, 2013, Biology of reproduction.

Ectopic class II major histocompatibility antigens in Hirschsprung's disease and neuronal intestinal dysplasia.

P. Donahoe, S. Kim, D. Doody, 1992, Journal of pediatric surgery.

Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

P. Donahoe, S. Maheswaran, F. Preffer, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mullerian inhibiting substance: an update.

P. Donahoe, J. Hutson, M. Mudgett-Hunter, 2002, Advances in experimental medicine and biology.

Effect of E. Coli endotoxin on mammalian cell growth and recombinant protein production

P. Donahoe, J. Epstein, M. M. Lee, 1990, In Vitro Cellular & Developmental Biology.

Mullerian Inhibiting Substance Gene Expression in the Cycling Rat Ovary Correlates with Recruited or Graafian Follicle Selection 1

M. L. Gustafson, P. Donahoe, D. Maclaughlin, 2004 .

Müllerian-Inhibiting Substance Type II Receptor Expression and Function in Purified Rat Leydig Cells.

P. Donahoe, F. Preffer, M. Hardy, 1999, Endocrinology.

Developmental expression of a candidate müllerian inhibiting substance type II receptor.

P. Donahoe, J. Teixeira, E. Catlin, 1996, Endocrinology.

Müllerian inhibiting substance gene expression in the cycling rat ovary correlates with recruited or graafian follicle selection.

M. L. Gustafson, P. Donahoe, D. Maclaughlin, 1994, Biology of reproduction.

Developmental changes in mullerian inhibiting substance in the cynomolgus monkey, Macaca fascicularis.

M. L. Gustafson, P. Donahoe, H. Keeping, 1994, The Journal of clinical endocrinology and metabolism.

Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-β family

P. Donahoe, T. B. Thompson, C. Harrison, 2021, Proceedings of the National Academy of Sciences.

Sex differentiation in mouse and man and subsequent development of the female reproductive organs

P. Donahoe, N. Arango, 2010 .

Aberrant colonic expression of MHC class II antigens in Hirschsprung's disease.

P. Donahoe, D. Doody, T. Kuroda, 1991, The Australian and New Zealand journal of surgery.

Management of neonates and children with male pseudohermaphroditism.

P. Donahoe, J. Crawford, W. Hendren, 1977, Journal of pediatric surgery.

Evaluation of the newborn with ambiguous genitalia.

P. Donahoe, W. Hendren, 1976, Pediatric clinics of North America.

Mullerian-Inhibiting Substance Induces Gro-β Expression in Breast Cancer Cells through a Nuclear Factor-κB–Dependent and Smad1-Dependent Mechanism

P. Donahoe, S. Maheswaran, V. Rangnekar, 2007 .

Retinoic acid-mediated differentiation protects against nitrofen-induced apoptosis.

P. Donahoe, J. Aidlen, D. E. Kling, 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

Müllerian inhibiting substance/anti-Müllerian hormone as a fertility preservation agent

P. Donahoe, D. Pépin, M. Sabatini, 2018, Current opinion in endocrinology, diabetes, and obesity.

The effect of fibronectin on cholinergic differentiation of the fetal colon.

P. Donahoe, S. Kamagata, 1985, Journal of pediatric surgery.

Differentiation of intramural ganglia in the dissociated rectosigmoid of the rat: an organ culture study.

P. Donahoe, W. Hendren, Y. Ito, 1977, Journal of pediatric surgery.

Single-cell sequencing reveals suppressive transcriptional programs regulated by MIS/AMH in neonatal ovaries

P. Donahoe, H. Horn, E. Oliva, 2021, Proceedings of the National Academy of Sciences.

Mixed gonadal dysgenesis, pathogensis, and management.

P. Donahoe, J. Crawford, W. Hendren, 1979, Journal of pediatric surgery.

Cholinergic nerve development of fetal lung in vitro.

P. Donahoe, Y. Morikawa, W. Hendren, 1978, Journal of pediatric surgery.

Quantification of Müllerian Inhibiting Substance/Anti-Müllerian Hormone polypeptide by isotope dilution mass spectrometry.

P. Donahoe, C. Burns, D. Pépin, 2018, Analytical biochemistry.

Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression.

P. Donahoe, L. Zhang, J. Teixeira, 2014, Developmental biology.

Donnai–Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy

P. Donahoe, N. S. Thomas, S. Kantarci, 2008, American journal of medical genetics. Part A.

De novo variants in congenital diaphragmatic hernia identify MYRF as a new syndrome and reveal genetic overlaps with other developmental disorders

W. Chung, Yufeng Shen, P. Donahoe, 2018, PLoS genetics.

AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer

Cesar M. Castro, P. Donahoe, M. Birrer, 2015, Proceedings of the National Academy of Sciences.

Focal Müllerian duct retention in male mice with constitutively activated β-catenin expression in the Müllerian duct mesenchyme

P. Donahoe, M. Taketo, P. Tanwar, 2010, Proceedings of the National Academy of Sciences.

Perspective: reproductive tract development--new discoveries and future directions.

P. Donahoe, D. Maclaughlin, J. Teixeira, 2001, Endocrinology.

Mullerian inhibiting substance acts as a motor neuron survival factor in vitro.

P. Donahoe, M. Kimber, A. McGeachie, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.

P. Donahoe, Mee-Ran Kim, Jang-Heub Kim, 2012, The Journal of clinical endocrinology and metabolism.

Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase.

P. Donahoe, M. White, J. Coughlin, 1989, Growth factors.

Intersex genetic anomalies with malignant potential

P. Donahoe, M. Fallat, 2006, Current opinion in pediatrics.

Sustained inquiry: in the clinic and at the bench.

P. Donahoe, 2004, Journal of pediatric surgery.

Bioassay, purification, cloning, and expression of müllerian inhibiting substance.

P. Donahoe, D. Maclaughlin, J. Epstein, 1991, Methods in enzymology.

Gonadotropins moderate rejection of trophic-specific congenic testes grafts.

P. Donahoe, E. Barksdale, T. G. McGenis, 1991, Journal of pediatric surgery.

Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.

P. Donahoe, K. Lyons, S. E. Yi, 2001, Molecular endocrinology.

Mechanism of action of Mullerian inhibiting substance.

P. Donahoe, J. Hutson, M. Fallat, 1984, Annual review of physiology.

Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.

P. Donahoe, G. Budzik, A. Fuller, 1982, The Journal of clinical endocrinology and metabolism.

Müllerian inhibiting substance as a marker for ovarian sex-cord tumor.

M. L. Gustafson, P. Donahoe, R. Scully, 1992, The New England journal of medicine.

Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance

P. Donahoe, P. Sluss, J. Teixeira, 2004, The Journal of Steroid Biochemistry and Molecular Biology.

Sex determination and differentiation.

P. Donahoe, D. Maclaughlin, 2004, The New England journal of medicine.

mechanisms of disease Sex Determination and Differentiation

P. Donahoe, D. Maclaughlin, 2004 .

Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.

P. Donahoe, A. Fuller, D. Maclaughlin, 1999, Gynecologic oncology.

Mutational Analysis of the Putative Anti-Müllerian Hormone (AMH) Binding Interface on its Type II Receptor, AMHR2

P. Donahoe, T. B. Thompson, D. Pépin, 2020, Endocrinology.

MIS/AMH in the assessment of cryptorchidism and intersex conditions

P. Donahoe, M. Misra, D. Maclaughlin, 2003, Molecular and Cellular Endocrinology.

Endogenous expression of Müllerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites.

P. Donahoe, Koji Watanabe, K. Watanabe, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads.

M. L. Gustafson, P. Donahoe, B. Silverman, 1997, The New England journal of medicine.

Müllerian inhibiting substance is present in embryonic testes of dogs with persistent müllerian duct syndrome.

P. Donahoe, V. Meyers-Wallen, D. Maclaughlin, 1989, Biology of reproduction.

An immunoassay to detect human müllerian inhibiting substance in males and females during normal development.

P. Donahoe, I. Dougas, R. Pepinsky, 1990, The Journal of clinical endocrinology and metabolism.

Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.

P. Donahoe, D. Powell, J. Epstein, 1992, Cancer research.

Developmentally regulated polyadenylation of two discrete messenger ribonucleic acids for müllerian inhibiting substance.

P. Donahoe, R. Cate, G. Waneck, 1992, Endocrinology.

Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.

P. Donahoe, T. Chin, R. L. Parry, 1991, Cancer research.

An immunoassay to detect human müllerian inhibiting substance in males and females during normal development.

P. Donahoe, I. Dougas, R. Pepinsky, 1990, The Journal of clinical endocrinology and metabolism.

Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.

P. Donahoe, D. V. Von Hoff, R. Hoffman, 1989, Cancer research.

Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment.

P. Donahoe, R. Mattaliano, R. Pepinsky, 1988, The Journal of biological chemistry.

Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.

P. Donahoe, T. Manganaro, S. Ueno, 1988, Endocrinology.

Immunocytochemical localization of Mullerian inhibiting substance in the rough endoplasmic reticulum and Golgi apparatus in Sertoli cells of the neonatal calf testis using a monoclonal antibody.

P. Donahoe, R. Trelstad, M. Hayashi, 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Mullerian inhibiting substance in human testes after birth.

P. Donahoe, Y. Morikawa, W. Hendren, 1977, Journal of pediatric surgery.

New insights into mullerian inhibiting substance and its mechanism of action.

P. Donahoe, A. Lane, 1998, The Journal of endocrinology.

Müllerian inhibiting substance as oocyte meiosis inhibitor

P. Donahoe, Masahīko Takahashi, S. Koide, 1986, Molecular and Cellular Endocrinology.

Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens.

P. Donahoe, J. Teixeira, C. Houk, 2004, Endocrinology.

Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.

P. Donahoe, J. Teixeira, A. Payne, 1999, Endocrinology.

Müllerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer.

P. Donahoe, D. Swann, A. Hayashi, 1979, Science.

Increased Secretion of Müllerian Inhibiting Substance after Immunological Blockade of Endogenous Luteinizing Hormone Releasing Hormone in the Rat

P. Donahoe, Y. Morikawa, I. Jackson, 1978, Pediatric Research.

Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat.

P. Donahoe, G. Cunha, M. Tsuji, 1992, Endocrinology.

Müllerian inhibiting substance in reproduction and cancer

P. Donahoe, 1992, Molecular reproduction and development.

Müllerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids.

P. Donahoe, S. Hirobe, M. M. Lee, 1991, Endocrinology.

Dysgenesis of testicular and streak gonads in the syndrome of mixed gonadal dysgenesis: perspective derived from a clinicopathologic analysis of twenty-one cases.

P. Donahoe, S. Robboy, W. Welch, 1982, Human pathology.

Human Miillerian Inhibiting Substance Inhibits Tumor Growth in Vitro and in Vivo1

P. Donahoe, T. Chin, R. L. Parry, 2006 .

Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive.

P. Donahoe, E. Catlin, D. Maclaughlin, 1996, Metabolism: clinical and experimental.

Müllerian inhibiting substance: New perspectives and future directions

P. Donahoe, E. Catlin, D. Maclaughlin, 1993, Microscopy research and technique.

Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.

P. Donahoe, E. Catlin, D. Powell, 1991, Metabolism: clinical and experimental.

Mullerian Inhibiting Substance Activity in the Development of the Reproductive Tract and Lung in the Fetus and Control of Oocyte Meiosis in the Adult

P. Donahoe, E. Catlin, D. Maclaughlin, 1991 .

Mullerian inhibiting substance ontogeny and its modulation by follicle-stimulating hormone in the rat testes.

P. Donahoe, D. Powell, C. Haqq, 1990, Endocrinology.

Mullerian Inhibiting Substance: Studies on its Mechanism of Action and Activity as an Anti-Tumor Agent

P. Donahoe, D. Maclaughlin, J. Epstein, 1989 .

Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase

P. Donahoe, J. Coughlin, G. Budzik, 1987, Molecular and Cellular Endocrinology.

Development of mullerian inhibiting substance as an anti-cancer drug.

P. Donahoe, E. G. Ninfa, R. Cate, 1986, Cold Spring Harbor symposia on quantitative biology.

Production of monoclonal antibodies for affinity purification of bovine mullerian inhibiting substance activity.

P. Donahoe, M. Mudgett-Hunter, G. Budzik, 1984, Hybridoma.

Mullerian inhibiting substance fractionation by dye affinity chromatography

P. Donahoe, G. Budzik, S. Kamagata, 1983, Cell.

A graded organ culture assay for the detection of Mullerian inhibiting substance.

P. Donahoe, W. Hendren, Y. Ito, 1977, The Journal of surgical research.

Müllerian inhibiting substance activity in bovine fetal, newborn and prepubertal testes.

P. Donahoe, W. Hendren, Y. Ito, 1977, Biology of reproduction.

Müllerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level1.

P. Donahoe, J. Teixeira, A. Payne, 1999, Endocrinology.

Fibroblast androgen receptors in patients with genitourinary anomalies.

P. Donahoe, J. Crawford, D. Loriaux, 1984, Journal of andrology.

Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

P. Donahoe, E. Oliva, B. Rueda, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Sex-specific fetal lung development and müllerian inhibiting substance.

P. Donahoe, E. Catlin, J. Epstein, 1990, The American review of respiratory disease.

Molecular Mechanisms of Mullerian Inhibiting Substance-Mediated Apoptosis

P. Donahoe, Tongwen Wang, 1997 .

Mullerian inhibiting substance binding and uptake

P. Donahoe, R. Ezzell, E. Catlin, 1992, Developmental dynamics : an official publication of the American Association of Anatomists.

Urinary phthalate metabolite concentrations are negatively associated with follicular fluid anti-müllerian hormone concentrations in women undergoing fertility treatment

P. Donahoe, R. Hauser, S. Mahalingaiah, 2020, Environment international.

Prenatal vitamin E treatment improves lung growth in fetal rats with congenital diaphragmatic hernia.

P. Donahoe, J. Schnitzer, G. Côté, 1999, Journal of pediatric surgery.

Biochemical immaturity of lungs in congenital diaphragmatic hernia.

P. Donahoe, J. Wain, E. Catlin, 1993, Journal of pediatric surgery.

Müllerian-Inhibiting Substance Inhibits Rat Leydig Cell Regeneration after Ethylene Dimethanesulphonate Ablation1

P. Donahoe, M. Hardy, C. Sottas, 2004, Biology of reproduction.

Müllerian Inhibiting Substance Regulates NFκB Signaling and Growth of Mammary Epithelial Cells in Vivo*

P. Donahoe, S. Maheswaran, D. Segev, 2001, The Journal of Biological Chemistry.

Follicular fluid anti-Müllerian hormone (AMH) concentrations and outcomes of in vitro fertilization cycles with fresh embryo transfer among women at a fertility center

Paige L. Williams, P. Donahoe, Lihua Zhang, 2020, Journal of Assisted Reproduction and Genetics.

Can fetal and newborn allografts survive in an immunocompetent host?

P. Donahoe, R. Foglia, M. LaQuaglia, 1986, Journal of pediatric surgery.

Androgen stimulation of nucleotide pyrophosphatase during mullerian duct regression.

P. Donahoe, J. Hutson, M. Fallat, 1984, Endocrinology.

Changing patterns of fibronectin, laminin, type IV collagen, and a basement membrane proteoglycan during rat Mullerian duct regression.

P. Donahoe, J. Hutson, R. Trelstad, 1984, Developmental biology.

Subrenal capsule assay to test the viability of parenterally delivered müllerian inhibiting substance.

P. Donahoe, A. Bogdén, G. Budzik, 1984, Journal of pediatric surgery.

Molecular biology of MIS and its receptors.

P. Donahoe, J. Teixeira, 1996, Journal of andrology.

Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.

P. Donahoe, A. Thanos, D. Vavvas, 2010, Protein expression and purification.

Involution of the female Mullerian duct of the fetal rat in the organ-culture assay for the detection of Mullerian Inhibiting Substance.

P. Donahoe, Y. Ito, J. Price, 1979, The American journal of anatomy.

Programmed cell death in the Müllerian duct induced by Müllerian inhibiting substance.

P. Donahoe, W. Hendren, Y. Ito, 1977, The American journal of anatomy.

Prenatal glucocorticoid therapy reverses pulmonary immaturity in congenital diaphragmatic hernia in fetal sheep.

P. Donahoe, P. Losty, J. Schnitzer, 1996, Annals of surgery.

Prenatal hormonal therapy for lung hypoplasia associated with congenital diaphragmatic hernia

P. Donahoe, P. Losty, J. Schnitzer, 1996 .

Bilateral rotated buttock flaps for vaginal atresia in severely masculinized females with adrenogenital syndrome.

G. Dumanian, P. Donahoe, 1992, Plastic and reconstructive surgery.

AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy

P. Donahoe, L. Zhang, H. Saatcioglu, 2017, Proceedings of the National Academy of Sciences.

The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.

P. Donahoe, B. Ransil, M. Seibel, 1992, The Journal of clinical endocrinology and metabolism.

Isolation of the bovine and human genes for müllerian inhibiting substance and expression of the human gene in animal cells

P. Donahoe, E. G. Ninfa, R. Mattaliano, 1986, Cell.

The Role of Zinc in Miillerian Duct Regression

P. Donahoe, J. Hutson, G. Budzik, 1982 .

Müllerian inhibiting substance inhibits an ovarian cancer cell line via β-catenin interacting protein deregulation of the Wnt signal pathway.

P. Donahoe, S. H. Park, Sang Il Kim, 2017, International journal of oncology.

Antenatal Glucocorticoid Corrects Pulmonary Immaturity in Experimentally Induced Congenital Diaphragmatic Hernia in Rats

P. Donahoe, H. Suen, K. Bloch, 1994, Pediatric Research.

Combined antenatal thyrotropin-releasing hormone and low-dose glucocorticoid therapy improves the pulmonary biochemical immaturity in congenital diaphragmatic hernia.

P. Donahoe, H. Suen, P. Losty, 1994, Journal of pediatric surgery.

Müllerian inhibiting substance depresses accumulation in vitro of disaturated phosphatidylcholine in fetal rat lung.

P. Donahoe, E. Catlin, T. Manganaro, 1988, American journal of obstetrics and gynecology.

Prenatal hormonal therapy improves pulmonary compliance in the nitrofen-induced CDH rat model.

P. Donahoe, H. Suen, P. Losty, 1995, Journal of pediatric surgery.

Polygenic Causes of Congenital Diaphragmatic Hernia Produce Common Lung Pathologies.

P. Donahoe, M. Longoni, F. High, 2016, The American journal of pathology.

herniahistology in rats with congenital diaphragmatic Prenatal hormones alter antioxidant enzymes and

P. Donahoe, D. Tibboel, J. D. Jongste, 2012 .

Congenital diaphragmatic hernia (CDH) etiology as revealed by pathway genetics

P. Donahoe, S. Kantarci, 2007, American journal of medical genetics. Part C, Seminars in medical genetics.

Decreased mitogen activated protein kinase activities in congenital diaphragmatic hernia-associated pulmonary hypoplasia.

P. Donahoe, L. Ercolani, A. Alessandrini, 2001, Journal of pediatric surgery.

Tracheal ligation increases mitogen-activated protein kinase activity and attenuates surfactant protein B mRNA in fetal sheep lungs.

P. Donahoe, J. Schnitzer, S. Islam, 1999, The Journal of surgical research.

Aspergillus-induced small bowel obstruction in a leukemic newborn.

P. Donahoe, S. Robboy, J. Raaf, 1977, Surgery.

The preservation of Mullerian inhibiting substance during long-term freezing of testicular fragments.

P. Donahoe, W. Hendren, Y. Ito, 1977, Cryobiology.

Correction of congenital abnormalities of the vagina and perineum.

P. Donahoe, W. Hendren, 1980, Journal of pediatric surgery.

Single-Stage Surgical Reconstruction for Infants With Congenital Adrenal Hyperplasia

P. Donahoe, D. Poppas, J. Schnitzer, 2003 .

Delay of testicular differentiation in the B6.YDOM ovotestis demonstrated by immunocytochemical staining for müllerian inhibiting substance.

P. Donahoe, T. Taketo, J. Saeed, 1991, Developmental biology.

Steroid modulation of Mullerian duct regression in the chick embryo.

P. Donahoe, J. Hutson, D. Maclaughlin, 1985, General and comparative endocrinology.

Specific estradiol binding in embryonic Mullerian ducts: a potential modulator of regression in the male and female chick.

P. Donahoe, J. Hutson, D. Maclaughlin, 1983, Endocrinology.

The ontogeny of Mullerian inhibiting substance in the gonads of the chicken.

P. Donahoe, J. Hutson, H. Ikawa, 1981, Journal of pediatric surgery.

The production of Mullerian inhibiting substance by the fetal, neonatal and adult rat.

P. Donahoe, S. Marfatia, W. Hendren, 1976, Biology of reproduction.

Salivary gland heterotopia in the lower part of the neck.

P. Donahoe, W. Adams, 1979, Archives of surgery.

Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease.

P. Donahoe, R. Schreiber, R. Kleinman, 1992, Gastroenterology.

Rejecti Model .on of Murine Congenic Bile Ducts: A for Immune-Mediated Bile Duct Disease

P. Donahoe, R. Schreiber, R. Kleinman, 1992 .

Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle.

P. Donahoe, D. Maclaughlin, T. Manganaro, 1989, Endocrinology.

Cellular localization of müllerian inhibiting substance in the developing rat ovary.

P. Donahoe, M. Takahashi, T. Manganaro, 1989, Endocrinology.

Müllerian inhibiting substance inhibits testosterone synthesis in adult rats.

P. Donahoe, M. Hardy, D. Maclaughlin, 2001, Journal of andrology.

Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents

P. Donahoe, P. Sluss, J. Teixeira, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Mullerian‐inhibiting substance secretion is delayed in XX sex‐reversed dog embryos

P. Donahoe, V. Meyers-Wallen, D. Maclaughlin, 1994, Molecular reproduction and development.

The critical period for mullerian duct regression in the dog embryo.

P. Donahoe, P. Concannon, V. Meyers-Wallen, 1991, Biology of reproduction.

The Biochemistry And Biology Of Müllerian Inhibiting Substance

P. Donahoe, D. Swann, G. Budzik, 1981 .

Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics

K. Brennand, P. Donahoe, F. Preffer, 2008, Proceedings of the National Academy of Sciences.

Mullerian inhibiting substance: an update.

P. Donahoe, D. Maclaughlin, 1982, Advances in experimental medicine and biology.

Pathogenesis and Treatment of Disorders of Sexual Development

P. Donahoe, R. Pieretti, 2018 .

Chapter 123 – Disorders of Sexual Development

P. Donahoe, R. Pieretti, 2012 .

Chapter 121 – Ambiguous Genitalia

P. Donahoe, J. Schnitzer, R. Pieretti, 2006 .

Clinical management of intersex abnormalities.

P. Donahoe, D. Powell, M. M. Lee, 1991, Current problems in surgery.

The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization.

P. Donahoe, M. Misra, D. Maclaughlin, 2003, The Journal of clinical endocrinology and metabolism.

Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications.

P. Donahoe, S. Maheswaran, J. Teixeira, 2001, Endocrine reviews.

True hermaphroditism: a clinical description and a proposed function for the long arm of the Y chromosome.

P. Donahoe, J. Crawford, W. Hendren, 1978, Journal of pediatric surgery.

Surgical treatment of congenital adrenal hyperplasia.

P. Donahoe, J. Schnitzer, 2001, Endocrinology and metabolism clinics of North America.

Müllerian inhibiting substance in sex-reversed dogs.

P. Donahoe, V. Meyers-Wallen, D. Patterson, 1987, Biology of reproduction.

Is Mullerian-inhibiting substance a circulating hormone in the chick-quail chimera?

P. Donahoe, J. Hutson, 1983, Endocrinology.

Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors

P. Donahoe, D. Maclaughlin, Jang‐Heub Kim, 2014, Obstetrics & gynecology science.

The hormonal control of testicular descent.

P. Donahoe, J. Hutson, 1986, Endocrine reviews.

Observations on the gubernaculum during descent of the testis.

P. Donahoe, Y. Morikawa, W. Hendren, 1979, Investigative urology.

Congenital adrenal hyperplasia: surgical considerations required to repair a 46,XX patient raised as a boy.

P. Donahoe, R. Dasgupta, J. Schnitzer, 2003, Journal of pediatric surgery.

The role of nucleotide pyrophosphatase in Mullerian duct regression.

P. Donahoe, J. Hutson, M. Fallat, 1983, Developmental biology.

Requirement for phosphatidylinositol-3'-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse.

P. Donahoe, J. Tilly, J L Tilly, 1999, Endocrinology.

Fetal and postnatal testis shows immunoprivilege as donor tissue.

D. E. Parks, P. Donahoe, R. Foglia, 1988, The Journal of urology.

SRYand architectural gene regulation: the kinetic stability of a bent protein-DNA complex can regulate its transcriptional potency.

P. Donahoe, W. Zhang, B. Li, 2001, Molecular endocrinology.

Erratum to: Type IV collagen drives alveolar epithelial–endothelial association and the morphogenetic movements of septation

P. Donahoe, N. Nagy, M. Jeanne, 2016, BMC Biology.

Type IV collagen drives alveolar epithelial–endothelial association and the morphogenetic movements of septation

P. Donahoe, N. Nagy, M. Jeanne, 2016, BMC Biology.

Title Type IV collagen drives alveolar epithelial-endothelial association and the morphogenetic movements of septation Permalink

P. Donahoe, N. Nagy, M. Jeanne, 2016 .

Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.

P. Donahoe, D. Schoenfeld, B. Silverman, 1996, The Journal of clinical endocrinology and metabolism.

Mullerian inhibiting substance: a gonadal hormone with multiple functions.

P. Donahoe, Mary M. Lee, M. M. Lee, 1993, Endocrine reviews.

Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance

P. Donahoe, Xiaolong Wei, F. Preffer, 2012, Proceedings of the National Academy of Sciences.

Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

P. Donahoe, D. Maclaughlin, 2010, Future oncology.

Mullerian Inhibiting Substance: A Potential Nontoxic, Naturally Occurring Therapeutic Agent for Certain Human Cancers

P. Donahoe, D. Maclaughlin, 2008 .

Steroid enhancement of Mullerian duct regression.

P. Donahoe, J. Hutson, G. Budzik, 1982, Journal of pediatric surgery.

Control of Müllerian Inhibiting Substance

P. Donahoe, Y. Morikawa, B. Bercu, 1981 .

Inhibition of Müllerian Inhibiting Substance Secretion by FSH

P. Donahoe, Y. Morikawa, I. Jackson, 1978, Pediatric Research.

Treatment of Male Infertility

P. Donahoe, J. Hutson, 1982 .

The Immunophilin FKBP12 Functions as a Common Inhibitor of the TGFβ Family Type I Receptors

P. Donahoe, P. Danielson, R. Lechleider, 1996, Cell.

Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism.

P. Donahoe, M. Misra, D. Maclaughlin, 2002, The Journal of clinical endocrinology and metabolism.

Molecular basis of mammalian sexual determination: activation of Müllerian inhibiting substance gene expression by SRY.

P. Donahoe, M. Weiss, C. Haqq, 1994, Science.

Müllerian inhibiting substance is present in testes of dogs with persistent müllerian duct syndrome.

P. Donahoe, V. Meyers-Wallen, D. Patterson, 1989, Biology of reproduction.

Masculinizing and feminizing syndromes caused by functioning tumors.

P. Donahoe, P. Masiakos, C. Flynn, 1997, Seminars in pediatric surgery.

The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling.

P. Donahoe, P. Danielson, T. Wang, 1996, Science.

Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants

Ryan Mills, Ji Hyeon Park, Aparna Prasad, 2011, Nature Biotechnology.

Transcriptional regulation of the rat Müllerian inhibiting substance type II receptor in rodent Leydig cells.

P. Donahoe, J. Teixeira, R. Antun, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Genome-wide enrichment of damaging de novo variants in patients with isolated and complex congenital diaphragmatic hernia

C. Bult, W. Chung, Yufeng Shen, 2017, Human Genetics.

Missense variants affecting the actin-binding domains of PLS3 cause X-linked congenital diaphragmatic hernia and body wall defects

C. Bult, P. Donahoe, P. Giampietro, 2021, medRxiv.

Rare and de novo variants in 827 congenital diaphragmatic hernia probands implicate LONP1 as candidate risk gene.

W. Chung, Yufeng Shen, P. Donahoe, 2021, American journal of human genetics.

HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis

P. Donahoe, T. Shioda, D. Sgroi, 2009, Proceedings of the National Academy of Sciences.

The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse.

P. Donahoe, M. Nomura, A. Feijen, 1998, Genes & development.

MiR-449a Affects Epithelial Proliferation during the Pseudoglandular and Canalicular Phases of Avian and Mammal Lung Development

P. Donahoe, K. Choy, A. Tracy, 2016, PloS one.

Distribution of ERK1/2 and ERK3 during normal rat fetal lung development

P. Donahoe, D. E. Kling, T. B. Kinane, 2006, Anatomy and Embryology.

Müllerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism*

P. Donahoe, S. Maheswaran, D. Segev, 2000, The Journal of Biological Chemistry.

Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer

P. Donahoe, E. Halpern, D. Dinulescu, 2006, Proceedings of the National Academy of Sciences.

Chick pulmonary Wnt5a directs airway and vascular tubulogenesis

P. Donahoe, D. Roberts, J. Hu, 2008, Development.

Complications of vaginal atresia in association with a duplicated mullerian duct.

P. Donahoe, R. Foglia, S. Kim, 1987, Journal of pediatric surgery.

Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression

P. Donahoe, J. Teixeira, N. Arango, 2006, Development.

Findings from aCGH in patients with congenital diaphragmatic hernia (CDH): A possible locus for Fryns syndrome

P. Donahoe, L. Holmes, C. Lee, 2006, American journal of medical genetics. Part A.

Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis.

P. Donahoe, K. Miyazono, Seong-Jin Kim, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Congenital diaphragmatic hernia candidate genes derived from embryonic transcriptomes

C. Bult, K. Lage, P. Donahoe, 2012, Proceedings of the National Academy of Sciences.

Pneumoperitoneum secondary to pulmonary air leak.

P. Donahoe, W. Hendren, D. Stewart, 1972, The Journal of pediatrics.

Mullerian-Inhibiting Substance

P. Donahoe, R. Cate, D. Maclaughlin, 1990 .

Primary genitourinary tuberculosis: rapid progression and tissue destruction during treatment.

P. Donahoe, K. Psihramis, 1986, The Journal of urology.

Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice.

P. Donahoe, G. Budzik, A. Fuller, 1984, Gynecologic oncology.

SRY recognizes conserved DNA sites in sex-specific promoters.

P. Donahoe, M. Weiss, C. Haqq, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFκB-mediated Pathway*

P. Donahoe, S. Maheswaran, D. Segev, 2000, The Journal of Biological Chemistry.

Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism.

P. Donahoe, S. Maheswaran, D. Segev, 2006, Molecular endocrinology.

Mullerian-inhibiting substance regulates NF–κB signaling in the prostate in vitro and in vivo

P. Donahoe, S. Maheswaran, D. Segev, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors.

P. Donahoe, Tongwen Wang, 2004, Frontiers in bioscience : a journal and virtual library.

Toward understanding the developmental anatomy of congenital diaphragmatic hernia.

P. Donahoe, P. Losty, J. Schnitzer, 1996, Clinics in perinatology.

Congenital diaphragmatic hernia and chromosome 15q26: determination of a candidate region by use of fluorescent in situ hybridization and array-based comparative genomic hybridization.

P. Donahoe, D. Tibboel, C. Lee, 2005, American journal of human genetics.

Mullerian inhibiting substance messenger ribonucleic acid expression in granulosa and Sertoli cells coincides with their mitotic activity.

P. Donahoe, W. He, S. Hirobe, 1992, Endocrinology.

Anti-Mullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.

P. Donahoe, P. Sluss, G. Greendale, 2020, The Journal of clinical endocrinology and metabolism.

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

Peter T Masiakos, Patricia K Donahoe, P. Donahoe, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Mullerian Inhibiting Substance Promotes Interferon γ-induced Gene Expression and Apoptosis in Breast Cancer Cells*

P. Donahoe, S. Maheswaran, E. Brachtel, 2003, Journal of Biological Chemistry.

Ambiguous genitalia.

P. Donahoe, M. M. Lee, 1994, Current therapy in endocrinology and metabolism.

Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells.

P. Donahoe, F. Preffer, M. Hardy, 1999, Endocrinology.

Type IV laryngotracheoesophageal clefts: surgical management for long-term survival.

P. Donahoe, S. Kim, J. Schnitzer, 1996, Journal of pediatric surgery.

Laryngotracheoesophageal cleft (type IV): management and repair of lesions beyond the carina.

P. Donahoe, S. Kim, D. Muehrcke, 1991, Journal of pediatric surgery.

Preputial unfurling to correct the buried penis.

P. Donahoe, M. Keating, 1986, Journal of pediatric surgery.

Genetic tools and algorithms for gene discovery in major congenital anomalies.

K. Lage, P. Donahoe, K. Noonan, 2009, Birth defects research. Part A, Clinical and molecular teratology.

Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics

P. Donahoe, P. Mueller, Xiaolong Wei, 2010, Proceedings of the National Academy of Sciences.

Infants with Bochdalek diaphragmatic hernia: Sibling precurrence and monozygotic twin discordance in a hospital‐based malformation surveillance program

P. Donahoe, M. Westgate, A. Lin, 2005, American journal of medical genetics. Part A.

Management and long-term follow-up of patients with types III and IV laryngotracheoesophageal clefts.

P. Donahoe, A. Kawaguchi, D. Ryan, 2005, Journal of pediatric surgery.

Complete laryngotracheoesophageal cleft: management and repair.

P. Donahoe, P. Gee, 1984, Journal of pediatric surgery.

The surgical management of laryngotracheoesophageal cleft with tracheoesophageal fistula and esophageal atresia.

P. Donahoe, W. Hendren, 1972, Surgery.

Characterization of the chromosome 1q41q42.12 region, and the candidate gene DISP1, in patients with CDH

Sibel Kantarci, Carrie Sougnez, Eli Hatchwell, 2010, American journal of medical genetics. Part A.

Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes

Dian Donnai, Graeme C.M. Black, Nicolas Chassaing, 2007, Nature Genetics.

Congenital diaphragmatic hernia--does the side of the defect influence the incidence of associated malformations?

P. Donahoe, D. Lloyd, P. Losty, 1998, Journal of pediatric surgery.

Embryonic cell death patterns associated with nitrofen-induced congenital diaphragmatic hernia.

P. Donahoe, P. Losty, J. Schnitzer, 1995, Journal of pediatric surgery.

Early one-stage surgical reconstruction of the extremely high vagina in patients with congenital adrenal hyperplasia.

M. L. Gustafson, P. Donahoe, 1994, Journal of pediatric surgery.

Acetylcholinesterase and manometry in the diagnosis of the constipated child.

P. Donahoe, S. Kim, W. Hendren, 1986, Archives of surgery.

Advances in management of laryngeal and subglottic stenosis.

P. Donahoe, M. Strome, 1982, Journal of pediatric surgery.

Cryotherapy of subglottic hemangioma.

P. Donahoe, M. Strome, N. Adzick, 1984, Journal of pediatric surgery.

Crossed renal ectopia in children.

P. Donahoe, R. Pfister, W. Hendren, 1976, Urology.

Pelvic kidney in infants and children: experience with 16 cases.

P. Donahoe, W. Hendren, 1980, Journal of pediatric surgery.

Prevalence and penetrance of ZFPM2 mutations and deletions causing congenital diaphragmatic hernia

K. Lage, P. Donahoe, A. Kashani, 2015, Clinical genetics.

Molecular pathogenesis of congenital diaphragmatic hernia revealed by exome sequencing, developmental data, and bioinformatics

C. Bult, K. Lage, P. Donahoe, 2014, Proceedings of the National Academy of Sciences.

A transforming growth factor beta type I receptor that signals to activate gene expression.

M. L. Gustafson, P. Donahoe, X. F. Wang, 1994, Science.

The p21RAS Farnesyltransferase α Subunit in TGF-β and Activin Signaling

Patricia K. Donahoe, Tongwen Wang, P. Donahoe, 1996, Science.

The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo.

P. Donahoe, A. Feijen, J. V. Raaij, 1999, Development.

Single-cell sequencing of neonatal uterus reveals an Misr2+ endometrial progenitor indispensable for fertility

K. Lage, P. Donahoe, H. Horn, 2019, eLife.

Maturation of the rectoanal response in premature and perinatal infants.

P. Donahoe, W. Hendren, Y. Ito, 1977, Journal of pediatric surgery.

An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: application to the four-way DNA junction.

P. Donahoe, M. Weiss, C. King, 1995, Biochemistry.

Müllerian-Inhibiting Substance: Critical Roles in Sexual Differentiation

M. L. Gustafson, P. Donahoe, 1994 .

Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor‐β type II receptor family

M. L. Gustafson, P. Donahoe, W. He, 1993, Developmental dynamics : an official publication of the American Association of Anatomists.

Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.

P. Donahoe, D. Maclaughlin, T. Manganaro, 1992, Endocrinology.

Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects.

P. Donahoe, M. Ahmad, D. Maclaughlin, 1992, Protein expression and purification.

Muscle surface pH as a monitor of tissue perfusion and acid-base status.

P. Donahoe, R. Filler, G. Haase, 1971, Journal of pediatric surgery.

Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct.

P. Donahoe, N. Arango, A. Fujino, 2009, Developmental biology.

A single heteromeric receptor complex is sufficient to mediate biological effects of transforming growth factor-beta ligands.

P. Donahoe, X. F. Wang, C. Bassing, 1994, The Journal of biological chemistry.

Perspective: Reproductive Tract Development-New Discoveries and Future Directions.

P. Donahoe, D. Maclaughlin, J. Teixeira, 2001, Endocrinology.

Sexual dimorphism of g‐protein subunit Gng13 expression in the cortical region of the developing mouse ovary

P. Donahoe, N. Arango, A. Fujino, 2007, Developmental dynamics : an official publication of the American Association of Anatomists.

Human Müllerian-Inhibiting Substance Promoter Contains a Functional TFII-I-Binding Initiator1

P. Donahoe, Koji Watanabe, A. Roy, 2000, Biology of reproduction.

Roux-en-Y on-line intussusception to avoid ascending cholangitis in biliary atresia.

P. Donahoe, W. Hendren, 1983, Archives of surgery.

Müllerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities.

M. L. Gustafson, P. Donahoe, D. Maclaughlin, 1993, Journal of pediatric surgery.

The inferior epigastric vein as an alternate site for central venous hyperalimentation.

P. Donahoe, S. Kim, 1980, Journal of pediatric surgery.

Manometry and histochemistry in the diagnosis of Hirschsprung's disease.

P. Donahoe, Y. Morikawa, W. Hendren, 1979, Pediatrics.

Accurate method to study static volume-pressure relationships in small fetal and neonatal animals.

P. Donahoe, H. Suen, P. Losty, 1994, Journal of applied physiology.

Male sex determination: current concepts of male sexual differentiation.

M. L. Gustafson, P. Donahoe, 1994, Annual review of medicine.

The fate of the grafted quail Mullerian duct in the chick embryonic coelom.

P. Donahoe, J. Hutson, M. Fallat, 1984, Journal of pediatric surgery.

Congenital diaphragmatic hernia interval on chromosome 8p23.1 characterized by genetics and protein interaction networks

E. Zackai, K. Lage, P. Donahoe, 2012, American journal of medical genetics. Part A.

Systematic analysis of copy number variation associated with congenital diaphragmatic hernia

P. Donahoe, Mallory Ryan, Chengsheng Zhang, 2018, Proceedings of the National Academy of Sciences.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2004. A 23-day-old infant with hypospadias and failure to thrive.

P. Donahoe, J. Stoler, N. Leach, 2004, The New England journal of medicine.

Neoadjuvant Treatment With Müllerian-Inhibiting Substance Synchronizes Follicles and Enhances Superovulation Yield

P. Donahoe, H. Saatcioglu, Lihua Zhang, 2019, Journal of the Endocrine Society.

Adult Mouse Myometrial Label‐Retaining Cells Divide in Response to Gonadotropin Stimulation

P. Donahoe, L. Zhang, F. Preffer, 2007, Stem cells.

Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

P. Donahoe, Xiaolong Wei, R. Pieretti-Vanmarcke, 2011, Gynecologic oncology.

A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives

P. Donahoe, D. Pépin, Marie-Charlotte Meinsohn, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Rare and de novo variants in 827 congenital diaphragmatic hernia probands implicate LONP1 and ALYREF as new candidate risk genes

P. Donahoe, B. Vardarajan, D. Potoka, 2021, medRxiv.

Expression analysis and evolutionary conservation of the mouse germ cell–specific D6Mm5e gene

P. Donahoe, N. Arango, A. Fujino, 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

Isolation of the rat gene for Mullerian inhibiting substance.

P. Donahoe, R. Tizard, C. Haqq, 1992, Genomics.

(Mullerian inhibiting substance/P450 aromatase/transcription factors/DNA-binding proteins/sexual dimorphism)

P. Donahoe, C. Haqq, Michael A. WEISStt, 2016 .

Update on the analysis of the need for pediatric surgeons in the United States.

P. Donahoe, A. Cnaan, W. Neblett, 1995, Journal of pediatric surgery.

Obturator bypass graft in radical excision of inguinal neoplasm.

P. Donahoe, D. Nabseth, R. A. Froio, 1967, Annals of surgery.

Gastroesophageal reflux and hiatus hernia in children: experience with 70 cases.

P. Donahoe, S. Kim, W. Hendren, 1980, Journal of pediatric surgery.

Periductal and matrix glycosaminoglycans in rat Mullerian duct development and regression.

P. Donahoe, R. Trelstad, G. Budzik, 1982, Developmental biology.

Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications

P. Donahoe, S. Maheswaran, J. Teixeira, 2003, Molecular and Cellular Endocrinology.

New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity.

P. Donahoe, J. Teixeira, N. Pahlavan, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107

P. Donahoe, S. Maheswaran, D. Barbie, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Müllerian inhibiting substance is anterogradely transported and does not attenuate avulsion-induced death of hypoglossal motor neurons

P. Donahoe, A. Clarkson, I. McLennan, 2011, Experimental Neurology.

Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.

P. Donahoe, S. Maheswaran, D. Segev, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Mullerian-inhibiting substanc signaling in the prostate in i

P. Donahoe, D. Segev, M. Hoshiya, 2016 .

Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene.

P. Donahoe, D. Maclaughlin, W. Cromie, 2003, Birth defects research. Part A, Clinical and molecular teratology.

FOXP1 Haploinsufficiency Contributes to the Development of Congenital Diaphragmatic Hernia

C. Shaw, P. Donahoe, I. Campbell, 2021, Journal of Pediatric Genetics.

Genomic structure and expression analysis of the mouse testis-specific ribbon protein (Trib) gene.

P. Donahoe, J. Teixeira, N. Arango, 2004, Gene.

se 1 modulates transforming ig in the regulation

P. Donahoe, K. Miyazono, T. Seki, 2016 .

Bile duct perforation in a newborn with stenosis of the ampulla of Vater.

P. Donahoe, W. Hendren, 1976, Journal of pediatric surgery.

Cholinergic nerve development in fetal lung.

P. Donahoe, Y. Morikawa, W. Hendren, 1978, Developmental biology.

Liver regeneration during immunosuppression.

P. Donahoe, W. Russell, W. Austen, 1987, Journal of Pediatric Surgery.

Evaluation of the infant who has ambiguous genitalia, and principles of operative management.

P. Donahoe, J. Schnitzer, 1996, Seminars in pediatric surgery.

CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis

Cesar M. Castro, K. Lage, P. Donahoe, 2016, PloS one.

Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.

P. Donahoe, W. Cliby, E. Leof, 2016, Current molecular medicine.

Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.

P. Donahoe, S. Nam, Mee-Ran Kim, 2011, International journal of oncology.

Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.

P. Donahoe, J. Cha, Mee-Ran Kim, 2012, International journal of oncology.

Stainless steel mesh supports high density cell growth and production of recombinant Mullerian Inhibiting Substances

P. Donahoe, J. Epstein, P. Hudson, 1989, In Vitro Cellular & Developmental Biology.

Detection of Müllerian inhibiting substance in biological samples by a solid phase sandwich radioimmunoassay.

P. Donahoe, M. LaQuaglia, M. Mudgett-Hunter, 1986, Endocrinology.

Towards international standardization of immunoassays for Müllerian inhibiting substance/anti-Müllerian hormone

P. Donahoe, C. Burns, D. Pépin, 2018, Reproductive biomedicine online.

Identification of a receptor for human müllerian inhibiting substance.

M. L. Gustafson, P. Donahoe, R. Ezzell, 1993, Endocrinology.

Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

P. Donahoe, S. Maheswaran, J. Green, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesis

P. Donahoe, S. Nam, Mee-Ran Kim, 2015, International journal of oncology.

Genomic approaches to surgical diseases: 21st annual Samuel Jason Mixter lecture.

P. Donahoe, 2006, Archives of surgery.

Mullerian inhibiting substance: a fetal hormone with surgical implications.

P. Donahoe, J. Hutson, G. Budzik, 1985, The Australian and New Zealand journal of surgery.

Estrogen inhibition of Mullerian inhibiting substance in the chick embryo.

P. Donahoe, J. Hutson, H. Ikawa, 1982, Journal of pediatric surgery.

Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells.

P. Donahoe, S. Maheswaran, E. Brachtel, 2003, Journal of Biological Chemistry.

Abstract A42: An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant c-terminal Mullerian inhibiting substance

P. Donahoe, D. Vavvas, D. Pépin, 2013 .

Development of a sexually differentiated behavior and its underlying CNS arousal functions.

D. Pfaff, P. Donahoe, L. Kow, 2007, Current topics in developmental biology.

Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.

Arlan F. Fuller, Patricia K. Donahoe, P. Donahoe, 1981 .

Enhanced purification of Mullerian inhibiting substance by lectin affinity chromatography

P. Donahoe, D. Swann, G. Budzik, 1980, Cell.

Liver transplantation in pediatric patients.

P. Donahoe, J. Vacanti, R. Kleinman, 1985, Advances in pediatrics.

Modulation by sphingolipids of calcium signals evoked by epidermal growth factor.

P. Donahoe, J. Blusztajn, M. Liscovitch, 1994, The Journal of biological chemistry.

Genetic analysis of de novo variants reveals sex differences in complex and isolated congenital diaphragmatic hernia and indicates MYRF as a candidate gene

W. Chung, D. Nickerson, Yufeng Shen, 2017, bioRxiv.

Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics (Proceedings of the National Academy of Sciences of the United States of America (2008) 105, 34, (12469-12473) DOI: 10.1073/pnas.0805012105)

K. Brennand, P. Donahoe, F. Preffer, 2008 .

Luteinizing hormone-releasing hormone-induced delay of parturition.

P. Donahoe, M. Soloff, M. Poth, 1980, Endocrinology.

Nitrofen induces a redox-dependent apoptosis associated with increased p38 activity in P19 teratocarcinoma cells.

P. Donahoe, J. Aidlen, D. E. Kling, 2005, Toxicology in vitro : an international journal published in association with BIBRA.

Complications of pediatric percutaneous renal procedures: incidence and observations.

P. Donahoe, J. Newhouse, S. Kim, 1983, The Urologic clinics of North America.

Prenatal hormonal therapy improves pulmonary morphology in rats with congenital diaphragmatic hernia.

P. Donahoe, P. Losty, J. Schnitzer, 1996, The Journal of surgical research.

A single-cell atlas of the cycling murine ovary

B. Sabatini, P. Donahoe, M. Hyun, 2022, bioRxiv.

Cancer-associated mesothelial cells are regulated by the anti-Müllerian hormone axis.

C. Bult, P. Donahoe, A. Mitra, 2023, Cell reports.

Neoseminal vesicle created from retained mullerian duct to preserve the vas in male infants.

P. Donahoe, 1988, Journal of pediatric surgery.

Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.

P. Donahoe, S. Maheswaran, V. Rangnekar, 2007, Cancer Research.

Mullerian inhibiting substance: a gonadal hormone with multiple Mullerian inhibiting substance: a gonadal hormone with multiple functions functions

P. Donahoe, Mary M. Lee, 2022 .

Sertoli cell production of müllerian inhibiting substance in vitro.

P. Donahoe, M. LaQuaglia, M. Takahashi, 1986, The Journal of urology.

Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation

P. Donahoe, P. Sluss, G. Greendale, 2020 .

A pediatric surgeon retools in genetics and genomics to study congenital diaphragmatic hernia.

P. Donahoe, 2009, Journal of pediatric surgery.

Urinary phthalate metabolite concentrations are negatively associated with follicular fluid anti-müllerian hormone concentrations in women undergoing fertility treatment

P. Donahoe, R. Hauser, S. Mahalingaiah, 2021, Environment international.

The Endocrine Society 2004 annual awards.

P. Donahoe, 2004, Endocrine reviews.

Cyclic adenosine 3',5'-monophosphate modulation of mullerian duct regression.

P. Donahoe, J. Hutson, G. Budzik, 1984, Endocrinology.

Extraction of Mullerian inhibiting substance from newborn calf testis.

P. Donahoe, D. Swann, Y. Morikawa, 1979, Developmental biology.

THEREOF FORTREATMENT OF CANCER AND EXCESS ANDROGEN STATES

P. Donahoe, 2017 .

Urinary phthalate metabolite concentrations are negatively associated with follicular fluid anti-müllerian hormone concentrations in women undergoing fertility treatment

Paige L. Williams, P. Donahoe, R. Hauser, 2021, Environment international.

Improved histology for the chick-quail chimera.

P. Donahoe, J. Hutson, 1984, Stain technology.

Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development

M. Daly, J. Rosenfeld, L. Shaffer, 2012, Proceedings of the National Academy of Sciences.

Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics

K. Brennand, P. Donahoe, F. Preffer, 2008, Proceedings of the National Academy of Sciences.

Focal Müllerian duct retention in male mice with constitutively activated β-catenin expression in the Müllerian duct mesenchyme

P. Donahoe, M. Taketo, P. Tanwar, 2010, Proceedings of the National Academy of Sciences.

Chick pulmonary Wnt5a directs airway and vascular tubulogenesis

P. Donahoe, D. Roberts, J. Hu, 2008, Development.

Durable contraception in the female domestic cat using viral-vectored delivery of a feline anti-Müllerian hormone transgene

P. Donahoe, H. Saatcioglu, D. Pépin, 2023, Nature communications.

Congenital diaphragmatic hernia candidate genes derived from embryonic transcriptomes

C. Bult, K. Lage, P. Donahoe, 2012, Proceedings of the National Academy of Sciences.

Conditional deletion of β-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium

P. Donahoe, E. Oliva, J. Teixeira, 2005 .